CD19 and acute lymphoblastic leukemia: Impressive responses have been achieved in some patients with relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL), chronic lymphocytic leukemia, and B-cell lymphoma after infusion of autologous CD19 chimeric antigen receptor (CAR)-T cells1–4.